Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Barbara Ellers‐Lenz"'
Treatment effectiveness in a rare oncology indication: Lessons from an external control cohort study
Autor:
Dina Oksen, Patricia Prince, Emmanuelle Boutmy, Elizabeth M. Garry, Barbara Ellers‐Lenz, Adina Estrin, Andreas Johne, Patrice Verpillat, Nicolle M. Gatto
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 8, Pp 1990-1998 (2022)
Abstract Real‐world data (RWD) reflecting patient treatment in routine clinical practice can be used to develop external control groups for single‐arm trials. External controls can provide valuable benchmark results on potential comparator drug e
Externí odkaz:
https://doaj.org/article/2ca7f2e918c842a88cefcea8b7b2b902
Autor:
Apostolia-Maria Tsimberidou, Jamie V. Shaw, Dejan Juric, Claire Verschraegen, Amy M. Weise, John Sarantopoulos, Gilberto Lopes, John Nemunaitis, Monica Mita, Haeseong Park, Barbara Ellers-Lenz, Hui Tian, Wenyuan Xiong, Remigiusz Kaleta, Razelle Kurzrock
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-10 (2021)
Abstract Background The PI3K/AKT/mTOR (PAM) pathway is a key regulator of tumor therapy resistance. We investigated M2698, an oral p70S6K/AKT dual inhibitor, in patients with advanced cancer who failed standard therapies. Methods M2698 was administer
Externí odkaz:
https://doaj.org/article/a4b6ff9c3cf54aeebe10a0ef9f20a8b8
Autor:
Jessica C Hassel, Celeste Lebbe, Paul Nghiem, Felix Kiecker, Sandra P D'Angelo, Andrew S Brohl, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Gülseren Güzel, Laurent Mortier, Jean-Jacques Grob, Nicola Fazio, Natalie Prinzi, Glenn J Hanna
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Background Avelumab (anti-programmed death ligand 1 (PD-L1)) is approved in multiple countries for the treatment of metastatic Merkel cell carcinoma (mMCC), a rare and aggressive skin cancer. We report efficacy and safety data and exploratory biomark
Externí odkaz:
https://doaj.org/article/85e056c7b681425bb8513b5bb24a5913
Autor:
Celeste Lebbe, Omid Hamid, Shailender Bhatia, Janice M Mehnert, Patrick Terheyden, Michele Milella, Isaac Brownell, Sandra P D'Angelo, Andrew S Brohl, Kent C Shih, Karl D Lewis, Gerald P Linette, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Marcis Bajars, Gülseren Güzel, Paul T Nghiem
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) became the first approved treatment for patients with metastatic MCC (mMC
Externí odkaz:
https://doaj.org/article/38f487d0c8524f31899d14e4888ffca6
Autor:
Egbert F Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye M Tho, Xiuning Le, Julien Mazieres, How S Hin, Masahire Morise, Viola W Zhu, Daniel Tan, Kristina H Holmberg, Barbara Ellers-Lenz, Svenja Adrian, Sabine Brutlach, Karl M Schumacher, Niki Karachaliou, Yi-Long Wu
Publikováno v:
Future Oncology. 18:1039-1054
MET amplification (METamp), a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors, occurs in up to 30% of patients with non-small-cell lung cancer (NSCLC) progressing on first-line osimertinib. Combining osimertinib with a MET inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4c5b96a113868d2d819fcd3ed9a4f3a
https://doi.org/10.2217/fon-2021-1406
https://doi.org/10.2217/fon-2021-1406
Autor:
Egbert, F Smit, Christophe, Dooms, Jo, Raskin, Ernest, Nadal, Lye M, Tho, Xiuning, Le, Julien, Mazieres, How, S Hin, Masahire, Morise, Viola, W Zhu, Daniel, Tan, Kristina, H Holmberg, Barbara, Ellers-Lenz, Svenja, Adrian, Sabine, Brutlach, Karl M, Schumacher, Niki, Karachaliou, Yi-Long, Wu
Publikováno v:
Future oncology (London, England). 18(9)
Osimertinib is used to treat a type of lung cancer that has specific changes (mutations) in a gene called
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::47a030a95679cd310cb1dc7f22888d9a
https://pubmed.ncbi.nlm.nih.gov/34918545
https://pubmed.ncbi.nlm.nih.gov/34918545
Autor:
Sara Georges, Sandra P. D'Angelo, Paul Nghiem, Gülseren Güzel, Andrew S. Brohl, Laurent Mortier, Jean-Jacques Grob, Parantu Shah, Felix Kiecker, Natalie Prinzi, Jessica C. Hassel, Glenn J. Hanna, Nicola Fazio, Barbara Ellers-Lenz, Céleste Lebbé
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundAvelumab (anti-programmed death ligand 1 (PD-L1)) is approved in multiple countries for the treatment of metastatic Merkel cell carcinoma (mMCC), a rare and aggressive skin cancer. We report efficacy and safety data and exploratory biomarke
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c00ff4d1f8a3cfecc6f0026ec61eccb6
https://jitc.bmj.com/content/9/7/e002646.full
https://jitc.bmj.com/content/9/7/e002646.full
Autor:
Claire F. Verschraegen, Hui Tian, John Sarantopoulos, Amy M. Weise, Apostolia Maria Tsimberidou, Razelle Kurzrock, John Nemunaitis, Dejan Juric, Barbara Ellers-Lenz, Gilberto Lopes, Haeseong Park, R. Kaleta, Monica M. Mita, Jamie V. Shaw, Wenyuan Xiong
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-10 (2021)
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-10 (2021)
Background The PI3K/AKT/mTOR (PAM) pathway is a key regulator of tumor therapy resistance. We investigated M2698, an oral p70S6K/AKT dual inhibitor, in patients with advanced cancer who failed standard therapies. Methods M2698 was administered as mon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::575e6af672c23d9dbc2a3efd892a4172
https://pubmed.ncbi.nlm.nih.gov/34407844
https://pubmed.ncbi.nlm.nih.gov/34407844
Autor:
Christophe Dooms, Remi Veillon, Niki Karachaliou, Masayuki Takeda, Egbert F. Smit, S. Abdul, T.L. Mun, Daniel Shao-Weng Tan, Barbara Ellers-Lenz, Xiuning Le, Jo Raskin, Santiago Viteri, Marie Wislez, Soon Hin How, Yi-Long Wu, Ingel K. Demedts, Ernest Nadal, Chin-Chou Wang, J. Mazieres
Publikováno v:
Journal of Thoracic Oncology. 16:S1099-S1100
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4419d87033d83cbc7a12a6c90e52996
https://doi.org/10.1016/j.jtho.2021.08.502
https://doi.org/10.1016/j.jtho.2021.08.502
Autor:
Céleste Lebbé, Mickaël Henry-Szatkowski, Jean J. Grob, Paul Nghiem, Sandra Nolte, Marcis Bajars, Andrew S. Brohl, Laurent Mortier, Murtuza Bharmal, Glenn J. Hanna, Matthias Hunger, Michael Schlichting, Gülseren Güzel, Sandra P. D'Angelo, Jessica C. Hassel, Barbara Ellers-Lenz, Nicola Fazio, Felix Kiecker, Sara Pusceddu
Publikováno v:
Future oncology (London, England). 16(27)
Aim: To evaluate changes in health-related quality of life (HRQoL) in a Phase II trial (NCT02155647) of treatment-naive patients with metastatic Merkel cell carcinoma treated with avelumab (15-month follow-up). Materials & methods: Mixed-effect Model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::448a3df717665608f941d88c89c544f8
https://pubmed.ncbi.nlm.nih.gov/32938212
https://pubmed.ncbi.nlm.nih.gov/32938212